Similar results were obtained in Fig. 4M and N. These survival analysis results showed that this H3K4me3-lncRNA score could provide better patient enrollment criteria for tumor immunotherapy targeting CD4+ or CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.